Lit­tle Nor­we­gian biotech will sell it­self for parts, as it plans to ex­plore 's­trate­gic op­tion­s'

A few weeks af­ter an­nounc­ing a re­or­ga­ni­za­tion and shut­ting down its on­ly clin­i­cal tri­al, Nordic Nanovec­tor has de­cid­ed to es­sen­tial­ly call it quits.

The Nor­we­gian …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER